AGEN - アジェナス (Agenus Inc.) アジェナス

 AGENのチャート


 AGENの企業情報

symbol AGEN
会社名 Agenus Inc (アジェナス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アジェナス(Agenus Inc.)は免疫腫瘍学(I-O)会社である。同社は癌と戦うために身体の免疫システムに関わる治療法の発見と開発に従事する。同社は、ヒト抗体を産生するように設計されたレトロサイトディスプレイ、SECANT酵母ディスプレイおよびファージディスプレイ技術を含む抗体発見プラットフォーム、チェックポイントモジュレーター(CPM)プログラムを含む抗体候補プログラム、並びにProphage、AutoSynVax、PhosPhoSynVax及びQS-21スチムロンアジュバント(QS-21スチムロン)を主とするサポニンベースのワクチンアジュバントを含むワクチンプログラムなどのプラットフォームとプログラムによって駆動されるI-Oポートフォリオを開発している。同社の発見パイプラインには、一連のチェックポイント変調(CPM)抗体が含まれる。ワクチンプラットフォームには、その熱ショックタンパク質(HSP)ベースのプロファージワクチン候補、およびその合成ワクチン候補のASVとPSVが含まれる。   アジェナスは米国のバイオ医薬品メ―カ―。主に、がん治療を目的に、免疫システム機能を調節するチェックポイント調節因子を標的とした抗体医薬品の発見、開発、商用化に従事。脳腫瘍、腎臓がん、肺がん、アルツハイマ―などの免疫治療用ワクチンの研究を行う。本社はマサチュ―セッツ州。   Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
本社所在地 3 Forbes Road Lexington MA 02421 USA
代表者氏名 Garo H. Armen ガロ・アーメン
代表者役職名 Chairman of the Board Chief Executive Officer Founder
電話番号 +1 781-674-4410
設立年月日 1994年
市場名 NASDAQ Small Cap
ipoyear 2000年
従業員数 255人
url www.agenusbio.com
nasdaq_url https://www.nasdaq.com/symbol/agen
adr_tso
EBITDA EBITDA(百万ドル) -113.91800
終値(lastsale) 2.07
時価総額(marketcap) 234493980.12
時価総額 時価総額(百万ドル) 223.16580
売上高 売上高(百万ドル) 29.24434
企業価値(EV) 企業価値(EV)(百万ドル) 193.05562
当期純利益 当期純利益(百万ドル) -150.89400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Agenus Inc revenues decreased 44% to $17.5M. Net loss applicable to common stockholders increased 61% to $78.9M. Revenues reflect Revenue (research and development) decrease of 61% to $12.1M. Higher net loss reflects Non-operating income (expense) decrease from $2.4M (income) to $1.4M (expense) GENERAL AND ADMINISTRATIVE increase of 23% to $16.3M (expense).

 AGENのテクニカル分析


 AGENのニュース

   Agenus' (AGEN) IND for iNKT Therapy Gets FDA Acceptance  2020/05/14 15:56:00 Zacks Investment Research
The FDA clears Agenus' (AGEN) IND application for allogeneic iNKT therapy, agenT-797, which is being developed to treat cancer as well as the deadly COVID-19 pandemic.
   FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy  2020/05/13 13:54:00 PR Newswire
/PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and…
   Agenus (AGEN) Upgraded to Buy: Here's Why  2020/05/11 16:00:06 Zacks Investment Research
Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
   Are Options Traders Betting on a Big Move in Agenus (AGEN) Stock?  2020/04/16 12:38:00 Zacks Investment Research
Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
   Agenus' (AGEN) IND for iNKT Therapy Gets FDA Acceptance  2020/05/14 15:56:00 Zacks Investment Research
The FDA clears Agenus' (AGEN) IND application for allogeneic iNKT therapy, agenT-797, which is being developed to treat cancer as well as the deadly COVID-19 pandemic.
   FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy  2020/05/13 13:54:00 PR Newswire
/PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and…
   Agenus (AGEN) Upgraded to Buy: Here's Why  2020/05/11 16:00:06 Zacks Investment Research
Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
   Are Options Traders Betting on a Big Move in Agenus (AGEN) Stock?  2020/04/16 12:38:00 Zacks Investment Research
Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
   Agenus (AGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y  2020/03/13 10:57:00 Zacks Investment Research
Agenus (AGEN) betters loss estimates and also beats on sales in the fourth quarter. The company gets a Fast Track tag for balstilimab & zalifrelimab combo to address the second-line cervical cancer.
   Agenus +2% on Q4 beat  2020/03/12 12:29:19 Seeking Alpha
Agenus (AGEN) Q4 results: Revenues: $34.5M (+430.8%). Net loss: ($30.9M) (+36.7%); loss/share: ($0.22) (+45.0%). Key Milestones Expected in 2020: 2 BLA fil
   AM Best Assigns Credit Ratings to Aseguradora General, S.A.  2020/03/04 19:35:00 Business Wire
MEXICO CITY--(BUSINESS WIRE)--AM Best has assigned a Financial Strength Rating of B++ (Good) and a Long-Term Issuer Credit Rating of “bbb” to Aseguradora General, S.A. (AGen) (Guatemala). The outlook assigned to these Credit Ratings (ratings) is stable. The ratings reflect AGen’s balance sheet strength, which AM Best categorizes as very strong, as well as its marginal operating performance, neutral business profile and appropriate enterprise risk management. The stable outlooks reflect the capa
   Agenus Announces Investor Day on February 20, 2020  2020/02/06 20:12:00 PR Newswire
LEXINGTON, Mass., Feb. 6, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced it will hold an Investor Day Thursday, February 20, 2020. The Investor Day will…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アジェナス AGEN Agenus Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)